|
시장보고서
상품코드
1807679
세계의 플라스미드 DNA 제조 시장 규모, 점유율, 동향, 업계 분석 : 등급별, 개발 단계별, 용도별, 질환별, 지역별 - 시장 예측(2025-2034년)Plasmid DNA Manufacturing Market Size, Share, Trends, Industry Analysis Report By Grade (R&D Grade, GMP Grade), By Development Phase, By Application, By Disease, By Region - Market Forecast, 2025-2034 |
||||||
Polaris Market Research의 최신 조사에 따르면 세계의 플라스미드 DNA 제조 시장 규모는 2034년까지 169억 5,000만 달러에 달할 전망입니다. 이 리포트는 현재 시장 역학의 상세 인사이트와 향후 시장 성장에 관한 분석을 제공하고 있습니다.
플라스미드 DNA 제조 산업은 플라스미드라는 작은 고리형 DNA 분자를 제조하는 산업입니다. 이러한 플라스미드는 생명공학 및 유전자 분석 및 연구에서 중요한 구성 요소입니다. 플라스미드는 유전물질을 운반하고 복제하기 위한 벡터로 사용되며, 다양한 첨단 치료 제품 개발 및 다양한 과학적 응용에 필수적입니다. 제조 공정에는 플라스미드의 설계부터 숙주세포배양에서의 증식, 특정 품질 기준을 충족하기 위한 최종 제품의 정제 및 분리까지 여러 단계가 포함됩니다.
플라스미드 DNA 제조 시장은 유전자 및 세포치료 분야의 확대에 힘입어 큰 폭으로 성장하고 있습니다. 플라스미드 DNA는 이러한 치료제뿐만 아니라 바이러스 벡터와 mRNA 백신의 제조에도 필수적인 원료입니다. 이러한 첨단 치료법의 임상시험이 증가함에 따라 고품질 임상용 플라스미드 DNA에 대한 수요도 증가하고 있습니다. 이에 따라 바이오 제약 산업 증가하는 수요에 대응하기 위해 제조 효율성과 확장성 향상에 초점을 맞추었습니다. 시장은 연구자 및 의약품 개발자의 다양한 요구에 부응하기 위해 다양한 서비스를 제공하는 대기업과 전문 수탁제조 조직이 혼합되어 시장을 형성하고 있습니다.
플라스미드 DNA 제조 시장 : 분석 개요
등급별로는 GMP 등급이 2024년 첨단 치료의 임상 및 상업용 수요가 높기 때문에 GMP 등급 부문이 가장 큰 점유율을 차지했습니다. 이러한 플라스미드는 안전성과 품질에 대한 엄격한 규제 기준을 충족해야 하므로, 이 분야는 새로운 치료제를 시장에 출시하는 데 필수적인 분야입니다.
개발 단계별로는 임상 치료제 부문이 2024년 가장 큰 점유율을 차지했습니다. 이는 현재 다양한 임상시험 단계에 있는 유전자 및 세포 치료제의 수가 방대하고 증가하고 있기 때문입니다. 이러한 임상시험에서 안정적인 고품질 플라스미드공급이 필요하다는 점이 이 분야가 주도적인 위치를 차지하는 주요 요인으로 작용하고 있습니다.
용도별로는 세포 및 유전자 치료 분야가 2024년 가장 큰 점유율을 차지했습니다. 플라스미드 DNA는 이러한 혁신적인 치료법을 만들어내는 핵심 요소이기 때문입니다. 암, 유전질환 등 질병에 대한 유전자 및 세포치료제 개발 및 상용화가 증가하고 있는 것이 이 분야가 시장을 독식하고 있는 주요 이유입니다.
질병별로는 다양한 암에 대한 유전자 치료, 면역 치료, 백신 개발에서 플라스미드 DNA의 사용이 증가함에 따라 암 분야가 2024년 가장 큰 점유율을 차지했습니다. 암의 높은 유병률과 이 분야의 지속적인 연구 노력으로 인해 플라스미드 DNA에 대한 상당한 수요가 지속적으로 창출되고 있습니다.
지역별로는 북미가 플라스미드 DNA 제조 세계 시장을 주도하고 있습니다. 이는 특히 미국의 경우 강력한 바이오의약품 산업, 광범위한 연구개발 인프라, 첨단 치료제 개발을 위한 막대한 자금이 존재하기 때문입니다. 아시아태평양은 플라스미드 DNA 제조를 위한 가장 빠르게 성장하는 시장으로 여겨지고 있습니다. 이는 인구 증가, 만성질환 유병률 증가, 의료비 지출 증가 등 복합적인 요인에 기인합니다.
플라스미드 DNA 제조 시장의 주요 기업에는 AGC Biologics, Aldevron (a Danaher Company), Akron Biotech, Catalent, Charles River Laboratories, GenScript ProBio, Kaneka Eurogentec S.A., Lonza, Nature Technology Corporation, PlasmidFactory GmbH & Co. KG, Thermo Fisher Scientific, Touchlight, VGXI, Inc. 등이 있습니다.
목차
제1장 서론
제2장 개요
제3장 분석 방법
제4장 세계의 플라스미드 DNA 제조 시장 인사이트
- 시장 스냅숏
- 플라스미드 DNA 제조 시장 역학
- 촉진요인과 기회
- 유전자·세포치료의 수요 증가
- DNA 백신·mRNA 백신의 개발 증가
- 억제요인과 과제
- 복잡한 규제 준수와 한정된 확장성
- 촉진요인과 기회
- PESTLE 분석
- 플라스미드 DNA 제조 시장의 동향
- 밸류체인 분석
- COVID-19의 영향 분석
제5장 세계의 플라스미드 DNA 제조 시장 : 등급별
- 주요 분석 결과
- 서론
- R&D 등급
- GMP 등급
제6장 세계의 플라스미드 DNA 제조 시장 : 개발 단계별
- 주요 분석 결과
- 서론
- 전임상 치료
- 임상 치료학
- 시판 치료제
제7장 세계의 플라스미드 DNA 제조 시장 : 용도별
- 주요 분석 결과
- 서론
- DNA 백신
- 세포·유전자 치료
- 면역치료
- 기타
제8장 세계의 플라스미드 DNA 제조 시장 : 질환별
- 주요 분석 결과
- 서론
- 감염증
- 암
- 유전성 질환
- 기타
제9장 세계의 플라스미드 DNA 제조 시장 : 지역별
- 주요 분석 결과
- 서론
- 플라스미드 DNA 제조 시장 분석 : 지역별(2020-2034년)
- 북미
- 북미 : 등급별(2020-2034년)
- 북미 : 개발 단계별(2020-2034년)
- 북미 : 용도별(2020-2034년)
- 북미 : 질병별(2020-2034년)
- 미국
- 캐나다
- 유럽
- 유럽 : 등급별(2020-2034년)
- 유럽 : 개발 단계별(2020-2034년)
- 유럽 : 용도별(2020-2034년)
- 유럽 : 질병별(2020-2034년)
- 영국
- 프랑스
- 독일
- 이탈리아
- 스페인
- 네덜란드
- 러시아
- 기타 유럽
- 아시아태평양
- 아시아태평양 : 등급별(2020-2034년)
- 아시아태평양 : 개발 단계별(2020-2034년)
- 아시아태평양 : 용도별(2020-2034년)
- 아시아태평양 : 질병별(2020-2034년)
- 중국
- 인도
- 말레이시아
- 일본
- 인도네시아
- 한국
- 호주
- 기타 아시아태평양
- 중동 및 아프리카
- 중동 및 아프리카 : 등급별(2020-2034년)
- 중동 및 아프리카 : 개발 단계별(2020-2034년)
- 중동 및 아프리카 : 용도별(2020-2034년)
- 중동 및 아프리카 : 질병별(2020-2034년)
- 사우디아라비아
- 아랍에미리트
- 이스라엘
- 남아프리카공화국
- 기타 중동 및 아프리카
- 라틴아메리카
- 라틴아메리카 : 등급별(2020-2034년)
- 라틴아메리카 : 개발 단계별(2020-2034년)
- 라틴아메리카 : 용도별(2020-2034년)
- 라틴아메리카 : 질병별(2020-2034년)
- 멕시코
- 브라질
- 아르헨티나
- 기타 라틴아메리카
제10장 경쟁 구도
- 사업 확대·기업 인수 분석
- 사업 확대
- 기업 인수
- 제휴/협업/합의/공개
제11장 기업 개요
- AGC Biologics
- Akron Biotech
- Aldevron(a Danaher Company)
- Catalent
- Charles River Laboratories
- GenScript ProBio
- Kaneka Eurogentec S.A.
- Lonza
- Nature Technology Corporation
- PlasmidFactory GmbH & Co. KG
- Thermo Fisher Scientific
- WuXi Biologics
The global plasmid DNA manufacturing market size is expected to reach USD 16.95 billion by 2034, according to a new study by Polaris Market Research. The report "Plasmid DNA Manufacturing Market Size, Share, Trends, Industry Analysis Report By Grade (R&D Grade, GMP Grade), By Development Phase, By Application, By Disease, By Region - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.
The plasmid DNA manufacturing industry involves the production of small, circular DNA molecules called plasmids. These plasmids are key components in biotechnology and genetic analysis and research. They are used as vectors to carry and replicate genetic material, which is essential for developing a range of advanced therapeutic products and for various scientific applications. The manufacturing process involves several steps, from designing the plasmid and growing it in a host cell culture to purifying and isolating the final product to meet specific quality standards.
The plasmid DNA manufacturing market is experiencing significant growth, driven by the expanding fields of gene and cell therapy. Plasmid DNA is a critical raw material for these therapies, as well as for the production of viral vectors and mRNA vaccines. As the number of clinical trials for these advanced treatments increases, the demand for high-quality, clinical-grade plasmid DNA is also rising. This has led to a focus on improving manufacturing efficiency and scalability to meet the growing needs of the biopharmaceutical industry. The market is supported by a mix of large companies and specialized contract manufacturing organizations that offer a range of services to meet the diverse needs of researchers and drug developers.
Plasmid DNA Manufacturing Market Report Highlights
By grade, the GMP grade segment held the largest share in 2024 due to the high demand for clinical and commercial use in advanced therapies. These plasmids must meet strict regulatory standards for safety and quality, which makes this segment essential for bringing new treatments to market.
By development phase, the clinical therapeutics segment held the largest share in 2024, driven by the large and growing number of gene and cell therapies currently in various stages of clinical trials. The need for a consistent and high-quality supply of plasmids for these trials is a major factor contributing to this segment's leading position.
In terms of application, the cell and gene therapy segment held the largest share in 2024, as plasmid DNA is a core component for creating these innovative treatments. The rising number of gene and cell therapies being developed and commercialized for diseases such as cancer and genetic disorders is the main reason for its market dominance.
By disease, the cancer segment held the largest share in 2024 because of the increasing use of plasmid DNA in developing gene therapies, immunotherapies, and vaccines for various cancers. The high prevalence of cancer and continuous research efforts in this area create a substantial and ongoing demand for plasmid DNA.
By region, North America leads the global market for plasmid DNA manufacturing. This is attributed to the presence of a strong biopharmaceutical industry, extensive research and development infrastructure, and significant funding for advanced therapeutic development, particularly in the U.S. The Asia Pacific is seen as the fastest-growing market for plasmid DNA manufacturing. This is due to a combination of factors, including a large population, a rising incidence of chronic diseases, and increasing healthcare spending.
A few key players in the plasmid DNA manufacturing market include AGC Biologics, Aldevron (a Danaher Company), Akron Biotech, Catalent, Charles River Laboratories, GenScript ProBio, Kaneka Eurogentec S.A., Lonza, Nature Technology Corporation, PlasmidFactory GmbH & Co. KG, Thermo Fisher Scientific, Touchlight, and VGXI, Inc.
Polaris Market Research has segmented the plasmid DNA manufacturing market report based on grade, development phase, application, disease, and region:
By Grade Outlook (Revenue - USD Billion, 2020-2034)
R&D Grade
GMP Grade
By Development Phase Outlook (Revenue - USD Billion, 2020-2034)
Pre-Clinical Therapeutics
Clinical Therapeutics
Marketed Therapeutics
By Application Outlook (Revenue - USD Billion, 2020-2034)
DNA Vaccines
Cell & Gene Therapy
Immunotherapy
Others
By Disease Outlook (Revenue - USD Billion, 2020-2034)
Infectious Disease
Cancer
Genetic Disorder
Others
By Regional Outlook (Revenue - USD Billion, 2020-2034)
North America
U.S.
Canada
Europe
Germany
France
UK
Italy
Spain
Netherlands
Russia
Rest of Europe
Asia Pacific
China
Japan
India
Malaysia
South Korea
Indonesia
Australia
Vietnam
Rest of Asia Pacific
Middle East & Africa
Saudi Arabia
UAE
Israel
South Africa
Rest of Middle East & Africa
Latin America
Mexico
Brazil
Argentina
Rest of Latin America
Table of Contents
1. Introduction
- 1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
- 1.2. Stakeholders
2. Executive Summary
- 2.1. Market Highlights
3. Research Methodology
- 3.1. Overview
- 3.1.1. Data Mining
- 3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources
4. Global Plasmid DNA Manufacturing Market Insights
- 4.1. Plasmid DNA Manufacturing Market - Market Snapshot
- 4.2. Plasmid DNA Manufacturing Market Dynamics
- 4.2.1. Drivers and Opportunities
- 4.2.1.1. Growing Demand for Gene and Cell Therapies
- 4.2.1.2. Increasing Development of DNA and mRNA Vaccines
- 4.2.2. Restraints and Challenges
- 4.2.2.1. Complex regulatory compliance and limited scalability
- 4.2.1. Drivers and Opportunities
- 4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
- 4.4. PESTEL Analysis
- 4.5. Plasmid DNA Manufacturing Market Trends
- 4.6. Value Chain Analysis
- 4.7. COVID-19 Impact Analysis
5. Global Plasmid DNA Manufacturing Market, by Grade
- 5.1. Key Findings
- 5.2. Introduction
- 5.2.1. Global Plasmid DNA Manufacturing Market, by Grade, 2020-2034 (USD Billion)
- 5.3. R&D Grade
- 5.3.1. Plasmid DNA Manufacturing Market, by R&D Grade, by Region, 2020-2034 (USD Billion)
- 5.4. GMP Grade
- 5.4.1. Plasmid DNA Manufacturing Market, by GMP Grade, by Region, 2020-2034 (USD Billion)
6. Global Plasmid DNA Manufacturing Market, by Development Phase
- 6.1. Key Findings
- 6.2. Introduction
- 6.2.1. Global Plasmid DNA Manufacturing Market, by Development Phase, 2020-2034 (USD Billion)
- 6.3. Pre-Clinical Therapeutics
- 6.3.1. Plasmid DNA Manufacturing Market, by Pre-Clinical Therapeutics, by Region, 2020-2034 (USD Billion)
- 6.4. Clinical Therapeutics
- 6.4.1. Plasmid DNA Manufacturing Market, by Clinical Therapeutics, by Region, 2020-2034 (USD Billion)
- 6.5. Marketed Therapeutics
- 6.5.1. Plasmid DNA Manufacturing Market, by Marketed Therapeutics, by Region, 2020-2034 (USD Billion)
7. Global Plasmid DNA Manufacturing Market, by Application
- 7.1. Key Findings
- 7.2. Introduction
- 7.2.1. Global Plasmid DNA Manufacturing Market, by Application, 2020-2034 (USD Billion)
- 7.3. DNA Vaccines
- 7.3.1. Plasmid DNA Manufacturing Market, by DNA Vaccines, by Region, 2020-2034 (USD Billion)
- 7.4. Cell & Gene Therapy
- 7.4.1. Plasmid DNA Manufacturing Market, by Cell & Gene Therapy, by Region, 2020-2034 (USD Billion)
- 7.5. Immunotherapy
- 7.5.1. Plasmid DNA Manufacturing Market, by Immunotherapy, by Region, 2020-2034 (USD Billion)
- 7.6. Others
- 7.6.1. Plasmid DNA Manufacturing Market, by Others, by Region, 2020-2034 (USD Billion)
8. Global Plasmid DNA Manufacturing Market, by Disease
- 8.1. Key Findings
- 8.2. Introduction
- 8.2.1. Global Plasmid DNA Manufacturing Market, by Disease, 2020-2034 (USD Billion)
- 8.3. Infectious Disease
- 8.3.1. Plasmid DNA Manufacturing Market, by Infectious Disease, by Region, 2020-2034 (USD Billion)
- 8.4. Cancer
- 8.4.1. Plasmid DNA Manufacturing Market, by Cancer, by Region, 2020-2034 (USD Billion)
- 8.5. Genetic Disorder
- 8.5.1. Plasmid DNA Manufacturing Market, by Genetic Disorder, by Region, 2020-2034 (USD Billion)
- 8.6. Others
- 8.6.1. Plasmid DNA Manufacturing Market, by Others, by Region, 2020-2034 (USD Billion)
9. Global Plasmid DNA Manufacturing Market, by Geography
- 9.1. Key Findings
- 9.2. Introduction
- 9.2.1. Plasmid DNA Manufacturing Market Assessment, By Geography, 2020-2034 (USD Billion)
- 9.3. Plasmid DNA Manufacturing Market - North America
- 9.3.1. North America: Plasmid DNA Manufacturing Market, by Grade, 2020-2034 (USD Billion)
- 9.3.2. North America: Plasmid DNA Manufacturing Market, by Development Phase, 2020-2034 (USD Billion)
- 9.3.3. North America: Plasmid DNA Manufacturing Market, by Application, 2020-2034 (USD Billion)
- 9.3.4. North America: Plasmid DNA Manufacturing Market, by Disease, 2020-2034 (USD Billion)
- 9.3.5. Plasmid DNA Manufacturing Market - US
- 9.3.5.1. US: Plasmid DNA Manufacturing Market, by Grade, 2020-2034 (USD Billion)
- 9.3.5.2. US: Plasmid DNA Manufacturing Market, by Development Phase, 2020-2034 (USD Billion)
- 9.3.5.3. US: Plasmid DNA Manufacturing Market, by Application, 2020-2034 (USD Billion)
- 9.3.5.4. US: Plasmid DNA Manufacturing Market, by Disease, 2020-2034 (USD Billion)
- 9.3.6. Plasmid DNA Manufacturing Market - Canada
- 9.3.6.1. Canada: Plasmid DNA Manufacturing Market, by Grade, 2020-2034 (USD Billion)
- 9.3.6.2. Canada: Plasmid DNA Manufacturing Market, by Development Phase, 2020-2034 (USD Billion)
- 9.3.6.3. Canada: Plasmid DNA Manufacturing Market, by Application, 2020-2034 (USD Billion)
- 9.3.6.4. Canada: Plasmid DNA Manufacturing Market, by Disease, 2020-2034 (USD Billion)
- 9.4. Plasmid DNA Manufacturing Market - Europe
- 9.4.1. Europe: Plasmid DNA Manufacturing Market, by Grade, 2020-2034 (USD Billion)
- 9.4.2. Europe: Plasmid DNA Manufacturing Market, by Development Phase, 2020-2034 (USD Billion)
- 9.4.3. Europe: Plasmid DNA Manufacturing Market, by Application, 2020-2034 (USD Billion)
- 9.4.4. Europe: Plasmid DNA Manufacturing Market, by Disease, 2020-2034 (USD Billion)
- 9.4.5. Plasmid DNA Manufacturing Market - UK
- 9.4.5.1. UK: Plasmid DNA Manufacturing Market, by Grade, 2020-2034 (USD Billion)
- 9.4.5.2. UK: Plasmid DNA Manufacturing Market, by Development Phase, 2020-2034 (USD Billion)
- 9.4.5.3. UK: Plasmid DNA Manufacturing Market, by Application, 2020-2034 (USD Billion)
- 9.4.5.4. UK: Plasmid DNA Manufacturing Market, by Disease, 2020-2034 (USD Billion)
- 9.4.6. Plasmid DNA Manufacturing Market - France
- 9.4.6.1. France: Plasmid DNA Manufacturing Market, by Grade, 2020-2034 (USD Billion)
- 9.4.6.2. France: Plasmid DNA Manufacturing Market, by Development Phase, 2020-2034 (USD Billion)
- 9.4.6.3. France: Plasmid DNA Manufacturing Market, by Application, 2020-2034 (USD Billion)
- 9.4.6.4. France: Plasmid DNA Manufacturing Market, by Disease, 2020-2034 (USD Billion)
- 9.4.7. Plasmid DNA Manufacturing Market - Germany
- 9.4.7.1. Germany: Plasmid DNA Manufacturing Market, by Grade, 2020-2034 (USD Billion)
- 9.4.7.2. Germany: Plasmid DNA Manufacturing Market, by Development Phase, 2020-2034 (USD Billion)
- 9.4.7.3. Germany: Plasmid DNA Manufacturing Market, by Application, 2020-2034 (USD Billion)
- 9.4.7.4. Germany: Plasmid DNA Manufacturing Market, by Disease, 2020-2034 (USD Billion)
- 9.4.8. Plasmid DNA Manufacturing Market - Italy
- 9.4.8.1. Italy: Plasmid DNA Manufacturing Market, by Grade, 2020-2034 (USD Billion)
- 9.4.8.2. Italy: Plasmid DNA Manufacturing Market, by Development Phase, 2020-2034 (USD Billion)
- 9.4.8.3. Italy: Plasmid DNA Manufacturing Market, by Application, 2020-2034 (USD Billion)
- 9.4.8.4. Italy: Plasmid DNA Manufacturing Market, by Disease, 2020-2034 (USD Billion)
- 9.4.9. Plasmid DNA Manufacturing Market - Spain
- 9.4.9.1. Spain: Plasmid DNA Manufacturing Market, by Grade, 2020-2034 (USD Billion)
- 9.4.9.2. Spain: Plasmid DNA Manufacturing Market, by Development Phase, 2020-2034 (USD Billion)
- 9.4.9.3. Spain: Plasmid DNA Manufacturing Market, by Application, 2020-2034 (USD Billion)
- 9.4.9.4. Spain: Plasmid DNA Manufacturing Market, by Disease, 2020-2034 (USD Billion)
- 9.4.10. Plasmid DNA Manufacturing Market - Netherlands
- 9.4.10.1. Netherlands: Plasmid DNA Manufacturing Market, by Grade, 2020-2034 (USD Billion)
- 9.4.10.2. Netherlands: Plasmid DNA Manufacturing Market, by Development Phase, 2020-2034 (USD Billion)
- 9.4.10.3. Netherlands: Plasmid DNA Manufacturing Market, by Application, 2020-2034 (USD Billion)
- 9.4.10.4. Netherlands: Plasmid DNA Manufacturing Market, by Disease, 2020-2034 (USD Billion)
- 9.4.11. Plasmid DNA Manufacturing Market - Russia
- 9.4.11.1. Russia: Plasmid DNA Manufacturing Market, by Grade, 2020-2034 (USD Billion)
- 9.4.11.2. Russia: Plasmid DNA Manufacturing Market, by Development Phase, 2020-2034 (USD Billion)
- 9.4.11.3. Russia: Plasmid DNA Manufacturing Market, by Application, 2020-2034 (USD Billion)
- 9.4.11.4. Russia: Plasmid DNA Manufacturing Market, by Disease, 2020-2034 (USD Billion)
- 9.4.12. Plasmid DNA Manufacturing Market - Rest of Europe
- 9.4.12.1. Rest of Europe: Plasmid DNA Manufacturing Market, by Grade, 2020-2034 (USD Billion)
- 9.4.12.2. Rest of Europe: Plasmid DNA Manufacturing Market, by Development Phase, 2020-2034 (USD Billion)
- 9.4.12.3. Rest of Europe: Plasmid DNA Manufacturing Market, by Application, 2020-2034 (USD Billion)
- 9.4.12.4. Rest of Europe: Plasmid DNA Manufacturing Market, by Disease, 2020-2034 (USD Billion)
- 9.5. Plasmid DNA Manufacturing Market - Asia Pacific
- 9.5.1. Asia Pacific: Plasmid DNA Manufacturing Market, by Grade, 2020-2034 (USD Billion)
- 9.5.2. Asia Pacific: Plasmid DNA Manufacturing Market, by Development Phase, 2020-2034 (USD Billion)
- 9.5.3. Asia Pacific: Plasmid DNA Manufacturing Market, by Application, 2020-2034 (USD Billion)
- 9.5.4. Asia Pacific: Plasmid DNA Manufacturing Market, by Disease, 2020-2034 (USD Billion)
- 9.5.5. Plasmid DNA Manufacturing Market - China
- 9.5.5.1. China: Plasmid DNA Manufacturing Market, by Grade, 2020-2034 (USD Billion)
- 9.5.5.2. China: Plasmid DNA Manufacturing Market, by Development Phase, 2020-2034 (USD Billion)
- 9.5.5.3. China: Plasmid DNA Manufacturing Market, by Application, 2020-2034 (USD Billion)
- 9.5.5.4. China: Plasmid DNA Manufacturing Market, by Disease, 2020-2034 (USD Billion)
- 9.5.6. Plasmid DNA Manufacturing Market - India
- 9.5.6.1. India: Plasmid DNA Manufacturing Market, by Grade, 2020-2034 (USD Billion)
- 9.5.6.2. India: Plasmid DNA Manufacturing Market, by Development Phase, 2020-2034 (USD Billion)
- 9.5.6.3. India: Plasmid DNA Manufacturing Market, by Application, 2020-2034 (USD Billion)
- 9.5.6.4. India: Plasmid DNA Manufacturing Market, by Disease, 2020-2034 (USD Billion)
- 9.5.7. Plasmid DNA Manufacturing Market - Malaysia
- 9.5.7.1. Malaysia: Plasmid DNA Manufacturing Market, by Grade, 2020-2034 (USD Billion)
- 9.5.7.2. Malaysia: Plasmid DNA Manufacturing Market, by Development Phase, 2020-2034 (USD Billion)
- 9.5.7.3. Malaysia: Plasmid DNA Manufacturing Market, by Application, 2020-2034 (USD Billion)
- 9.5.7.4. Malaysia: Plasmid DNA Manufacturing Market, by Disease, 2020-2034 (USD Billion)
- 9.5.8. Plasmid DNA Manufacturing Market - Japan
- 9.5.8.1. Japan: Plasmid DNA Manufacturing Market, by Grade, 2020-2034 (USD Billion)
- 9.5.8.2. Japan: Plasmid DNA Manufacturing Market, by Development Phase, 2020-2034 (USD Billion)
- 9.5.8.3. Japan: Plasmid DNA Manufacturing Market, by Application, 2020-2034 (USD Billion)
- 9.5.8.4. Japan: Plasmid DNA Manufacturing Market, by Disease, 2020-2034 (USD Billion)
- 9.5.9. Plasmid DNA Manufacturing Market - Indonesia
- 9.5.9.1. Indonesia: Plasmid DNA Manufacturing Market, by Grade, 2020-2034 (USD Billion)
- 9.5.9.2. Indonesia: Plasmid DNA Manufacturing Market, by Development Phase, 2020-2034 (USD Billion)
- 9.5.9.3. Indonesia: Plasmid DNA Manufacturing Market, by Application, 2020-2034 (USD Billion)
- 9.5.9.4. Indonesia: Plasmid DNA Manufacturing Market, by Disease, 2020-2034 (USD Billion)
- 9.5.10. Plasmid DNA Manufacturing Market - South Korea
- 9.5.10.1. South Korea: Plasmid DNA Manufacturing Market, by Grade, 2020-2034 (USD Billion)
- 9.5.10.2. South Korea: Plasmid DNA Manufacturing Market, by Development Phase, 2020-2034 (USD Billion)
- 9.5.10.3. South Korea: Plasmid DNA Manufacturing Market, by Application, 2020-2034 (USD Billion)
- 9.5.10.4. South Korea: Plasmid DNA Manufacturing Market, by Disease, 2020-2034 (USD Billion)
- 9.5.11. Plasmid DNA Manufacturing Market - Australia
- 9.5.11.1. Australia: Plasmid DNA Manufacturing Market, by Grade, 2020-2034 (USD Billion)
- 9.5.11.2. Australia: Plasmid DNA Manufacturing Market, by Development Phase, 2020-2034 (USD Billion)
- 9.5.11.3. Australia: Plasmid DNA Manufacturing Market, by Application, 2020-2034 (USD Billion)
- 9.5.11.4. Australia: Plasmid DNA Manufacturing Market, by Disease, 2020-2034 (USD Billion)
- 9.5.12. Plasmid DNA Manufacturing Market - Rest of Asia Pacific
- 9.5.12.1. Rest of Asia Pacific: Plasmid DNA Manufacturing Market, by Grade, 2020-2034 (USD Billion)
- 9.5.12.2. Rest of Asia Pacific: Plasmid DNA Manufacturing Market, by Development Phase, 2020-2034 (USD Billion)
- 9.5.12.3. Rest of Asia Pacific: Plasmid DNA Manufacturing Market, by Application, 2020-2034 (USD Billion)
- 9.5.12.4. Rest of Asia Pacific: Plasmid DNA Manufacturing Market, by Disease, 2020-2034 (USD Billion)
- 9.6. Plasmid DNA Manufacturing Market - Middle East & Africa
- 9.6.1. Middle East & Africa: Plasmid DNA Manufacturing Market, by Grade, 2020-2034 (USD Billion)
- 9.6.2. Middle East & Africa: Plasmid DNA Manufacturing Market, by Development Phase, 2020-2034 (USD Billion)
- 9.6.3. Middle East & Africa: Plasmid DNA Manufacturing Market, by Application, 2020-2034 (USD Billion)
- 9.6.4. Middle East & Africa: Plasmid DNA Manufacturing Market, by Disease, 2020-2034 (USD Billion)
- 9.6.5. Plasmid DNA Manufacturing Market - Saudi Arabia
- 9.6.5.1. Saudi Arabia: Plasmid DNA Manufacturing Market, by Grade, 2020-2034 (USD Billion)
- 9.6.5.2. Saudi Arabia: Plasmid DNA Manufacturing Market, by Development Phase, 2020-2034 (USD Billion)
- 9.6.5.3. Saudi Arabia: Plasmid DNA Manufacturing Market, by Application, 2020-2034 (USD Billion)
- 9.6.5.4. Saudi Arabia: Plasmid DNA Manufacturing Market, by Disease, 2020-2034 (USD Billion)
- 9.6.6. Plasmid DNA Manufacturing Market - UAE
- 9.6.6.1. UAE: Plasmid DNA Manufacturing Market, by Grade, 2020-2034 (USD Billion)
- 9.6.6.2. UAE: Plasmid DNA Manufacturing Market, by Development Phase, 2020-2034 (USD Billion)
- 9.6.6.3. UAE: Plasmid DNA Manufacturing Market, by Application, 2020-2034 (USD Billion)
- 9.6.6.4. UAE: Plasmid DNA Manufacturing Market, by Disease, 2020-2034 (USD Billion)
- 9.6.7. Plasmid DNA Manufacturing Market - Israel
- 9.6.7.1. Israel: Plasmid DNA Manufacturing Market, by Grade, 2020-2034 (USD Billion)
- 9.6.7.2. Israel: Plasmid DNA Manufacturing Market, by Development Phase, 2020-2034 (USD Billion)
- 9.6.7.3. Israel: Plasmid DNA Manufacturing Market, by Application, 2020-2034 (USD Billion)
- 9.6.7.4. Israel: Plasmid DNA Manufacturing Market, by Disease, 2020-2034 (USD Billion)
- 9.6.8. Plasmid DNA Manufacturing Market - South Africa
- 9.6.8.1. South Africa: Plasmid DNA Manufacturing Market, by Grade, 2020-2034 (USD Billion)
- 9.6.8.2. South Africa: Plasmid DNA Manufacturing Market, by Development Phase, 2020-2034 (USD Billion)
- 9.6.8.3. South Africa: Plasmid DNA Manufacturing Market, by Application, 2020-2034 (USD Billion)
- 9.6.8.4. South Africa: Plasmid DNA Manufacturing Market, by Disease, 2020-2034 (USD Billion)
- 9.6.9. Plasmid DNA Manufacturing Market - Rest of Middle East & Africa
- 9.6.9.1. Rest of Middle East & Africa: Plasmid DNA Manufacturing Market, by Grade, 2020-2034 (USD Billion)
- 9.6.9.2. Rest of Middle East & Africa: Plasmid DNA Manufacturing Market, by Development Phase, 2020-2034 (USD Billion)
- 9.6.9.3. Rest of Middle East & Africa: Plasmid DNA Manufacturing Market, by Application, 2020-2034 (USD Billion)
- 9.6.9.4. Rest of Middle East & Africa: Plasmid DNA Manufacturing Market, by Disease, 2020-2034 (USD Billion)
- 9.7. Plasmid DNA Manufacturing Market - Latin America
- 9.7.1. Latin America: Plasmid DNA Manufacturing Market, by Grade, 2020-2034 (USD Billion)
- 9.7.2. Latin America: Plasmid DNA Manufacturing Market, by Development Phase, 2020-2034 (USD Billion)
- 9.7.3. Latin America: Plasmid DNA Manufacturing Market, by Application, 2020-2034 (USD Billion)
- 9.7.4. Latin America: Plasmid DNA Manufacturing Market, by Disease, 2020-2034 (USD Billion)
- 9.7.5. Plasmid DNA Manufacturing Market - Mexico
- 9.7.5.1. Mexico: Plasmid DNA Manufacturing Market, by Grade, 2020-2034 (USD Billion)
- 9.7.5.2. Mexico: Plasmid DNA Manufacturing Market, by Development Phase, 2020-2034 (USD Billion)
- 9.7.5.3. Mexico: Plasmid DNA Manufacturing Market, by Application, 2020-2034 (USD Billion)
- 9.7.5.4. Mexico: Plasmid DNA Manufacturing Market, by Disease, 2020-2034 (USD Billion)
- 9.7.6. Plasmid DNA Manufacturing Market - Brazil
- 9.7.6.1. Brazil: Plasmid DNA Manufacturing Market, by Grade, 2020-2034 (USD Billion)
- 9.7.6.2. Brazil: Plasmid DNA Manufacturing Market, by Development Phase, 2020-2034 (USD Billion)
- 9.7.6.3. Brazil: Plasmid DNA Manufacturing Market, by Application, 2020-2034 (USD Billion)
- 9.7.6.4. Brazil: Plasmid DNA Manufacturing Market, by Disease, 2020-2034 (USD Billion)
- 9.7.7. Plasmid DNA Manufacturing Market - Argentina
- 9.7.7.1. Argentina: Plasmid DNA Manufacturing Market, by Grade, 2020-2034 (USD Billion)
- 9.7.7.2. Argentina: Plasmid DNA Manufacturing Market, by Development Phase, 2020-2034 (USD Billion)
- 9.7.7.3. Argentina: Plasmid DNA Manufacturing Market, by Application, 2020-2034 (USD Billion)
- 9.7.7.4. Argentina: Plasmid DNA Manufacturing Market, by Disease, 2020-2034 (USD Billion)
- 9.7.8. Plasmid DNA Manufacturing Market - Rest of Latin America
- 9.7.8.1. Rest of Latin America: Plasmid DNA Manufacturing Market, by Grade, 2020-2034 (USD Billion)
- 9.7.8.2. Rest of Latin America: Plasmid DNA Manufacturing Market, by Development Phase, 2020-2034 (USD Billion)
- 9.7.8.3. Rest of Latin America: Plasmid DNA Manufacturing Market, by Application, 2020-2034 (USD Billion)
- 9.7.8.4. Rest of Latin America: Plasmid DNA Manufacturing Market, by Disease, 2020-2034 (USD Billion)
10. Competitive Landscape
- 10.1. Expansion and Acquisition Analysis
- 10.1.1. Expansion
- 10.1.2. Acquisitions
- 10.2. Partnerships/Collaborations/Agreements/Exhibitions
11. Company Profiles
- 11.1. AGC Biologics
- 11.1.1. Company Overview
- 11.1.2. Financial Performance
- 11.1.3. Product Benchmarking
- 11.1.4. Recent Development
- 11.2. Akron Biotech
- 11.2.1. Company Overview
- 11.2.2. Financial Performance
- 11.2.3. Product Benchmarking
- 11.2.4. Recent Development
- 11.3. Aldevron (a Danaher Company)
- 11.3.1. Company Overview
- 11.3.2. Financial Performance
- 11.3.3. Product Benchmarking
- 11.3.4. Recent Development
- 11.4. Catalent
- 11.4.1. Company Overview
- 11.4.2. Financial Performance
- 11.4.3. Product Benchmarking
- 11.4.4. Recent Development
- 11.5. Charles River Laboratories
- 11.5.1. Company Overview
- 11.5.2. Financial Performance
- 11.5.3. Product Benchmarking
- 11.5.4. Recent Development
- 11.6. GenScript ProBio
- 11.6.1. Company Overview
- 11.6.2. Financial Performance
- 11.6.3. Product Benchmarking
- 11.6.4. Recent Development
- 11.7. Kaneka Eurogentec S.A.
- 11.7.1. Company Overview
- 11.7.2. Financial Performance
- 11.7.3. Product Benchmarking
- 11.7.4. Recent Development
- 11.8. Lonza
- 11.8.1. Company Overview
- 11.8.2. Financial Performance
- 11.8.3. Product Benchmarking
- 11.8.4. Recent Development
- 11.9. Nature Technology Corporation
- 11.9.1. Company Overview
- 11.9.2. Financial Performance
- 11.9.3. Product Benchmarking
- 11.9.4. Recent Development
- 11.10. PlasmidFactory GmbH & Co. KG
- 11.10.1. Company Overview
- 11.10.2. Financial Performance
- 11.10.3. Product Benchmarking
- 11.10.4. Recent Development
- 11.11. Thermo Fisher Scientific
- 11.11.1. Company Overview
- 11.11.2. Financial Performance
- 11.11.3. Product Benchmarking
- 11.11.4. Recent Development
- 11.12. WuXi Biologics
- 11.12.1. Company Overview
- 11.12.2. Financial Performance
- 11.12.3. Product Benchmarking
- 11.12.4. Recent Development
